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Abstract  
Background 
Urinary incontinence (UI) is highly prevalent in nursing and residential care homes (CH) and 
profoundly impacts on residents’ dignity and quality of life. Care homes predominantly use 
absorbent pads to contain UI rather than actively treat the condition. Transcutaneous posterior tibial 
nerve stimulation (TPTNS) is a non-invasive, safe, low-cost intervention with demonstrated 
effectiveness for reducing UI in adults. However, the effectiveness of TPTNS to treat UI in older 
adults living in care homes is not known.  The ELECTRIC Trial aims to establish if a programme of 
TPTNS is a clinically effective treatment for UI in care home residents and investigate the associated 
costs and consequences. 
 
Methods 
This is a pragmatic, multicentre, placebo controlled randomised parallel group trial comparing 
effectiveness of TPTNS (target n=250) with sham stimulation (target n=250) in reducing volume of UI 
in CH residents.  CH residents (men and women) with self- or staff- reported UI of more than once 
per week are eligible to take part, including those with cognitive impairment.  Outcomes will be 
measured at 6, 12 and 18 weeks post randomisation using the following measures: 24-hour pad 
weight tests (PWT), post void residual urine (bladder scans), Patient Perception of Bladder Condition 
(PPBC), Minnesota Toileting Skills Questionnaire (MTSQ) and Dementia Quality of Life (DEMQOL).  
Economic evaluation based on a bespoke Resource Use Questionnaire will assess the costs of 
providing a programme of TPTNS. A concurrent process evaluation will investigate fidelity to the 
intervention and influencing factors and qualitative interviews will explore the experiences of TPTNS 
from the perspective of CH residents, family members, CH staff and managers. 
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Discussion 
TPTNS is a non-invasive intervention that has demonstrated effectiveness in reducing UI in adults.  
The ELECTRIC Trial will involve CH staff delivering TPTNS to residents and establish whether TPTNS is 
more effective than sham stimulation for reducing the volume of UI in CH residents.   Should TPTNS 
be shown to be an effective and acceptable treatment for UI in older adults in CHs, it will provide a 
safe, low-cost and dignified alternative to the current standard approach of containment and 
medication. 
 
Trial registration 
Clinical Trials.gov. NCT03248362.  Registered on 14/08/2017.  https://clinicaltrials.gov/ 
ISRCTN, ISRCTN 98415244.  Registered on 25/04/2018. https://www.isrctn.com/ 
 
Keywords 
Care homes, nursing home, urinary incontinence, tibial nerve stimulation, older adults. 
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Introduction 
[6a] Background and rationale 
The highest prevalence of urinary incontinence (UI), defined by the International Continence Society 
as ‘any involuntary loss of urine’1, is found in residential or nursing care homes (CHs). UI is 
distressing for older adults and profoundly impacts on dignity and quality of life2. It is associated 
with impaired physical functioning3, cognitive impairment3-4, sleep disturbance2, falls5-6, fractures7 
Urinary Tract Infection (UTI)8, and hygiene and tissue viability problems9.  UI affects social 
participation and is a major cause of clinical depression and social isolation10-11.  UI is costly, to CH 
providers, health care services and the individual older adult. Direct personal and treatment costs 
are high.  Intangible costs associated with social isolation and withdrawal from community 
participation also occur10 but have not been quantified. 
 
The most common type of UI experienced by older CH residents is mixed UI, combining symptoms of 
overactive bladder (OAB -urgency, frequency, nocturia with or without urgency UI) with stress UI12.  
For most this is exacerbated by functional losses of urine associated with frailty13. No evidence of the 
effects of conservative interventions directly addressing mixed incontinence in CH populations is yet 
available12.  There is also a dearth of published evidence of interventions to promote recovery of 
bladder continence in the CH context14 or for people living with dementia, even though the CH 
population is three times more likely to have UI or faecal incontinence (FI) than people of equivalent 
age and characteristics15. The burden of UI in the care home population is significant and increasing3, 
yet evidence suggests that even intractable UI is amenable to interventions that may improve 
urinary function and quality of life16. Currently CHs use containment approaches, predominantly 
absorbent pads, rather than active treatment as the mainstay for managing UI8. Other non-
pharmacological options include bladder training17 and pelvic floor muscle training18 as well as 
toileting programmes, signage and environmental adaptations for people with dementia.  However, 
evidence indicates these are rarely used, have limited effectiveness in the CH environment and are 
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labour intensive19 which impacts on sustainability in the longer term. They also require a degree of 
cooperation, engagement and activity by the resident, which can be prohibitive for people with 
cognitive impairment14,20.  Anti-muscarinic drugs may be used to reduce urge/OAB problems 
however these are associated with significant adverse effects in frail older people and should be 
avoided in those with dementia as they may also counteract the functional benefits of 
anticholinesterase inhibitors21.  Newer β3-adrenergic receptor agonist drugs with potential benefit 
such as mirabegron are available but the frail CH population has not been included in drug trials and, 
with prevalent polypharmacy in such contexts, any additional medication may increase adverse 
effects22. 
 
Transcutaneous posterior tibial nerve stimulation (TPTNS) is a simple, non-invasive, safe and low-
cost intervention with promising effectiveness, directly targeting urgency or mixed UI23-24.  It uses a 
portable transcutaneous electrical nerve stimulation (TENS) machine to stimulate the posterior tibial 
nerve using surface electrodes placed adjacent to the medial malleolus. It does not require the 
resident to actively engage in order to receive the intervention, so is suitable for those who are 
physically and cognitively frail. It is comfortable to use25 and promotes dignified care as only access 
to the resident’s ankle is required.  It has been shown in randomised controlled trials (RCTs) to 
reduce UI in community-living older women24 and adults with neurogenic bladder dysfunction 
(including multiple sclerosis26, Parkinson’s27 and stroke28), however no definitive RCTs have focused 
on treating UI in the CH population.  A small randomised feasibility study indicated the safety, 
acceptability and potential effects of TPTNS in this context23. 
Although the exact mechanism of action has yet to be fully understood, TPTNS is believed to restore 
the balance between excitatory and inhibitory bladder functioning by modulating the signal traffic to 
and from the bladder through the sacral plexus29. It is hypothesised that stimulating afferent sacral 
nerves in the lower extremities increases the inhibitory stimuli to the efferent pelvic nerve, 
suppresses bladder afferent nerve activity, reduces detrusor contractility and increases bladder 
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capacity30 and by these means TPTNS reduces the sensation of urgency and the frequency of 
micturition, thus enabling improved bladder control. These mechanisms may also reduce the volume 
of urine retained in the bladder after voiding23,26. For the CH residents who wear absorbent pads 
because of mixed/urgency UI, TPTNS may reduce the sudden urge to urinate and frequency of 
voiding, allowing residents more time to reach the toilet, which in turn will enable more appropriate 
use of the toilet, generating respect and enhancing the person’s dignity. 
As a potentially therapeutic modality TPTNS could occupy a unique position in the CH care pathway 
for UI as it provides active treatment of the mixed/urgency UI condition without requiring any active 
contribution by the resident.  Thus, unusually, it is as likely to be of benefit to those with cognitive 
impairment as those without, and has been shown to be safe and not associated with any severe or 
limiting adverse effects.  Skin redness and potential skin allergy are the only mild adverse effects 
reported. 
 
A systematic review of TPTNS for UI identified ten RCTs31.  A total of 472 participants were included, 
only 30 of whom were from a single CH population. All studies reported improvements in bladder 
condition with TPTNS, in terms of symptom improvement and/or UI related quality of life, although 
no one trial was definitive. A meta-analysis (two trials) found a mean difference between TPTNS and 
control group in the self-reported International Consultation on Incontinence Questionnaire- Urinary 
Incontinence (ICIQ-UI) short-form score of -3.79 (95%CI -5.82,-1.76), considered a clinically 
meaningful effect32. There were no significant adverse events and TPTNS was consistently reported 
as safe. However, the studies in the meta-analysis were small (outcomes from 79 participants), with 
methodological weaknesses and a Grading of Recommendations Assessment, Development and 
Evaluation (GRADE)33 rating of ‘low quality’.  With the increases in the older adult population and 
concomitant multi-morbidities including dementia16, together with the associated increase in 
numbers with UI, especially OAB/urgency incontinence3,12, there is a pressing need to investigate 
interventions to treat UI to reduce the burden on CH residents and care providers.  
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[7] Objectives 
The ELECTRIC Trial will: 
1. Establish whether TPTNS is more effective than sham stimulation for reducing the volume of 
urinary incontinence at 6, 12 and 18 weeks, in CH residents. 
2. Investigate mediating factors that impact on the effectiveness of TPTNS in a mixed method, 
process evaluation involving fidelity assessment, implementation support and qualitative 
components. 
3. Undertake economic evaluation of TPTNS in CHs assessing the costs of providing the 
programme and presenting the findings alongside the key primary and secondary outcomes 
in a cost consequence analysis. 
4. Explore in an interview study the experiences of TPTNS from the perspectives of: 
• CH residents 
• Family carers 
• CH nurses and senior carers 
• CH managers 
 
[8] Trial design 
The research comprises a pragmatic, multicentre, placebo controlled randomised parallel group trial 
to compare effectiveness of TPTNS (target n=250) with sham stimulation (target n=250) to reduce 
volume of UI in CH residents. Results from an internal pilot with 100-140 residents will determine 
progression to the main trial. A longitudinal, mixed methods nested process evaluation will run in 
parallel with the RCT to investigate intervention fidelity and acceptability, as well as qualitative 
exploration of the intervention delivery and implementation support. An economic evaluation of 
TPTNS compared with usual continence care will be completed in the form of a cost consequence 
analysis. 
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Methods: Participants, interventions and outcomes 
[9] Study setting 
CHs (nursing or residential) for older adults in England and Scotland.  
  
[10] Eligibility criteria 
Inclusion criteria:  
CH residents will be eligible for inclusion if they have self- or staff- reported UI more than once per 
week; if they use the toilet or a toilet aid for bladder emptying with or without assistance and if they 
wear absorbent pads to contain urine.  
Exclusion criteria include CH residents with:   
1. an indwelling urinary catheter  
2. symptomatic UTI 
3. post-void residual urine (PVRU) volume more than 300ml  
4. a cardiac pacemaker  
5. treated epilepsy  
6. bilateral leg ulcers  
7. pelvic cancer (current) 
8. palliative care status or 
9. non-English speakers 
 
[26a] Who will take informed consent? 
Processes for identifying eligibility and participant recruitment will differ in England and Scotland 
according to relevant legislation on capacity to provide informed consent to participate. In both 
countries the local Principal Investigator (PI -senior clinical nurse or manager) in each CH will identify 
potentially eligible residents, provide study information to all those with capacity and seek 
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agreement from the resident for them to be approached by the Regional Research Assistant (RRA-
registered nurses working in trial regions in Scotland and England), to receive further information 
about the study. All resident recruitment will be undertaken by the RRAs.  In CHs in England in 
accordance with the Mental Capacity Act 200534, where the local PI believes a resident’s capacity is 
in question, they will identify and provide the information to the resident’s personal consultee 
(usually a family member or friend), or if one is not available, a nominated consultee identified by 
the CH study team and seek their agreement for an approach from the RRA. The RRA will provide a 
full explanation of the study, ensure eligibility and seek the consultee’s advice on what they feel the 
resident’s wishes would be about taking part in the trial, if they had capacity. The consultee will sign 
a declaration form if they believe the resident would choose to agree to participate.  In CHs in 
Scotland, in accordance with the Adults with Incapacity (Scotland) Act 200035, where a resident has a 
certificate of incapacity the local PI will identify and provide the study information to the resident’s 
welfare attorney (if one has been appointed) or their nearest relative. If there is no welfare attorney 
identified, or the resident does not have a relative who can be consulted, they will be considered 
ineligible to participate in the study. The local PI will seek agreement from the welfare 
attorney/nearest relative for the RRA to speak to them. The RRA will provide a full explanation of the 
study to the welfare attorney/nearest relative, ensure eligibility and seek written consent for the 
resident to participate.  Written consent to participate in the process evaluation interviews will be 
sought by the RRA from the individual family carers or care home staff prior to them taking part.    
 
[26b] Additional consent provisions for collection and use of participant data and biological 
specimens 
On the consent form, participants will be asked if they agree to use of their data should they choose 
to withdraw from the trial. Participants will also be asked for permission for the research team to 
share relevant data with people from the Universities taking part in the research or from regulatory 
authorities, where relevant.  This trial does not involve collecting biological specimens for storage. 
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[11] Interventions 
[6b] Explanation for the choice of comparators 
To ensure the resident and their relatives are blind to the allocated intervention group a sham 
stimulation intervention rather than a no-treatment comparator will be used. The sham stimulation 
will comprise low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned 
specifically on the lateral aspect of the ankle in order to avoid the tibial nerve, which runs close to 
the skin surface behind the medial malleolus. The cathode electrode will be positioned behind the 
lateral malleolus and the anode 10cm cephalad to it.  The stimulation parameters will be identical to 
the TPTNS stimulation other than the intensity of the current which will always be set at 4mA, not 
adjusted to individual comfort levels as it is in the TPTNS intervention group. The current will be 
initially increased until the resident reports feeling some sensation, following which the current will 
be reduced down to 4mA. All residents will be informed that they may not feel anything with this 
intervention and that this is quite normal. A previous pilot study23 found that older residents were 
unable to accurately identify their allocated group and confirmed the integrity of the sham 
stimulation protocol. 
   
[11a] Intervention description  
TPTNS is a form of peripheral neuromodulation. The tibial nerve, which lies immediately posterior to 
the medial malleolus will be stimulated electrically using a portable TENS machine and two surface 
electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 
10cm cephalad to it. Standardised stimulation parameters will be applied of 10 Hz frequency, 200µs-
1 pulse width, in continuous stimulation mode. Intensity of stimulation (mA-1) will be adjusted on a 
session-by-session basis according to individual resident highest tolerated intensity below the motor 
threshold that remains comfortable.  Both intervention and placebo/sham groups will receive an 
electrical stimulation programme comprising a total of 12 sessions of 30 minutes’ duration each, 
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delivered twice weekly over 6 weeks. The stimulation equipment and method of delivery will be 
identical in everything but the intensity of electrical stimulation applied and the positioning of the 
surface electrodes.  The electrical stimulators will be programmed to the set parameters and locked 
prior to individual use so that the only adjustable parameter will be the intensity of stimulation. The 
intervention will be delivered by CH registered nurses and senior carers who will receive specific 
training and support to undertake this role.   No strict TPTNS/sham intervention timetable will be set 
and individual CHs will have flexibility around where, how and when they deliver the sessions, 
bearing in mind that they should occur twice weekly for 30 minutes each, over a 6-week period. A 
proposed schedule for each home and resident will be agreed between the resident, registered 
nurse/senior carer and local PI at the point of treatment inception.   The allocated treatment (TPTNS 
or sham) will be offered to the resident a maximum of two times in any 24-hour period. If refused 
when first offered (verbally or by non-verbal behaviour) the treatment will be postponed for at least 
an hour and then offered one further time. Records of acceptance and refusals will be documented 
in the resident’s treatment diary. Adherence to the TPTNS or sham stimulation programme will be 
one of the progression criteria to full scale trial from the internal pilot. While aiming to complete a 
full 12-session programme over the 6-week intervention period contingency measures will be 
implemented if four or more sessions are refused by the resident or missed. Such measures will 
include approaching the resident at a later time, a different place or on a different day.  
 
[11b] Criteria for discontinuing or modifying allocated interventions 
There will be no special criteria for discontinuing or modifying allocated interventions. Residents will 
remain in the trial unless they (or their welfare attorney/nearest relative in Scotland) choose to 
withdraw consent, or if their personal or nominated consultee (in England) advises that they believe 
the person’s wishes about participation have changed, or they are unable to continue for a clinical 
reason, or if they die.   
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[11c] Strategies to improve adherence to interventions 
An individual resident stimulation diary will be completed by the registered nurse/senior carer 
following each session, recording date, time, intensity of electrical stimulation and any comments on 
the process of delivery. The locked stimulation machines will automatically record the total 
stimulation time in use and the average stimulation intensity of all recorded sessions, thus providing 
an objective record of the stimulation programme provided to each resident.  This recorded data will 
be compared against the individually written stimulation diary completed by the staff after each 
session. The fidelity comparison will be performed by an Implementation Support Facilitator (ISF) 
whose role will be to provide support and ongoing training to CH staff and ensure they are 
competent and confident to deliver the stimulations. Electrode positioning, indicating accuracy of 
allocated intervention will be recorded using a digital photograph taken by staff every two weeks 
during the intervention delivery period, and viewed by the ISF. 
 
[11d] Relevant concomitant care permitted or prohibited during the trial 
Implementing TPTNS or sham stimulation will not require alteration to current continence care 
pathways (including use of any medication) and these will continue in line with CH policies for both 
trial arms. 
 
[30] Provisions for post-trial care 
Each participating CH will be provided with electrical stimulator machines after the trial follow up 
period has been completed, should the homes wish to continue use of TPTNS. 
 
[12] Outcomes 
Table 1 summarises the outcomes assessed at baseline, 6-wek, 12-week and 18-week post 
randomisation assessments. 
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Table 1: Outcomes assessed at trial time points 
 
 
Baseline 6-week 12-weeks 18weeks Data collector 
24 hour PWT ● ● ● ● CH staff 
RRA 
Number of 
pads used 
● ● ● ● RRA 
72 hour 
bladder diary 
● ● ● ● CH staff 
PVRU 
 
● ● ● ● RRA 
PPBC 
 
● ● ● ● Resident and 
RRA 
FC-PBC 
 
● ● ● ● Family member  
S-PBC 
 
● ● ● ● SC/RN 
responsible for 
care provision 
MTSQ ● ● ● ● Resident and 
RRA  
MTSQ ● ● ● ● CH staff and 
RRA 
DEMQOL 
  
● ●  ● Resident  and 
RRA 
DEMQOL-
proxy 
● ●  ● Single, named 
proxy and RRA 
Resource 
Use 
Questionnaire 
● ●  ● RRA 
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Primary outcome measure 
The primary outcome is the volume of urine leaked over a 24-hour period at 6 weeks post 
randomisation.  
 
Secondary outcome measures  
Urinary outcomes:  
• Volume of urine leaked over a 24-hour period at 12 and 18 weeks post randomisation 
• Number of pads used in 24 hours at 6, 12 and 18 weeks post randomisation  
• PVRU at 6, 12 and 18 weeks post randomisation 
• The Patient Perception of Bladder Condition36 (PPBC) at 6, 12 and 18 weeks post 
randomisation 
• The Minnesota Toileting Skills Questionnaire37 (MTSQ) at 6, 12 and 18 weeks post 
randomisation 
 
Quality of Life outcomes 
• Resident Dementia Quality of Life (DEMQOL)38 at 6 and 18 weeks post randomisation 
• For those not able to complete themselves, a proxy DEMQOL38 at 6 and 18 weeks post 
randomisation 
 
Economic outcomes 
• Resource Use Questionnaire (RUQ) (Appendix 2) at 6 and 18 weeks post randomisation. 
 
 
[13] Participant timeline 
See Figure 1 for the resident flowchart. 
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Figure 1: Resident Flowchart 
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[14] Sample size  
A total of 500 residents will be recruited. The worthwhile difference it was believed the intervention 
may result in is a reduction of 200ml/24 hours in UI, equivalent to 200g in pad weight39.  There is a 
lack of data available on the standard deviation (SD) of Pad Weight Tests40 (PWT) in CH residents; 
however, a small RCT39 reported results on this outcome.  The SD from the trial was 450ml, but given 
the small and selected sample included the upper 95% confidence interval around the SD was 
estimated and found to be approximately 570ml/24 hours, hence the standardised effect size of 0.35 
(i.e. 200/570).  To detect that difference with 90% power at the two-sided 5% alpha level, primary 
outcome data on 344 participants will be required. The limited data available suggested that the 
intra-class correlation (ICC) for any possible clustering effect was likely to be negligible.  However the 
sample size will be inflated to 500 to compensate for attrition in the primary outcome due to death 
of CH residents and potential transfers to other CHs, estimated conservatively to be 30%40. 
 
 [15] Recruitment 
CHs with a minimum of 25 residents will be eligible to take part. The minimum population of 
residents will be 1700, although the expected number will be considerably higher. Approximately 
70% will have UI and 10% will be in receipt of palliative care or do not use the toilet/toilet aid for 
elimination, thus there will be an estimated minimum total pool of 1071 eligible residents from 
whom 500 will be recruited. Assuming similar recruitment rates to the HTA funded DCM-EPIC study 
undertaken in CHs of 60% of eligible CH residents41, this would provide at least 643 residents from 
whom to recruit a sample of 500. Recruitment will be undertaken over an 18-month period, 
commencing month 6 and completed by month 24. At least four new CH sites will be established 
every 3 months during the recruitment period, depending on CH size and location.  
 
Assignment of interventions: allocation 
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[16a] Sequence generation 
Eligible, consenting residents are randomised to one of the two groups (TPTNS or sham). 
Randomisation is computer allocated on a one to one basis in random permuted blocks of size two, 
four or six, with stratification by: 
• Sex – male/female 
• UI severity - mild (0-200ml/24 hrs); moderate (200-400ml /24 hrs); severe (400+ ml/24 hrs)  
• Centre (Care Home) 
 
[16b] Concealment mechanism 
Randomisation will utilise a proven web-based randomisation system, hosted by the Centre for 
Healthcare Randomised Trials Unit (CHaRT), which ensures allocation concealment.  
 
[16c] Implementation of allocation sequence 
The allocation sequence generation will be embedded in the trial web site.  After participants are 
enrolled, their baseline information will be entered onto the randomisation database remotely by 
the RRAs.  The randomisation results will be automatically generated and emailed to the ELECTRIC 
trial office, who will forward to the relevant local PI.  
 
Assignment of interventions: blinding 
[17a] Who will be blinded 
Information required to perform the randomisation will be submitted by the RRA, who obtained the 
consent, however to ensure the RRA is blinded to group allocation the information on the allocated 
group will be delivered to the local PI in each CH by the ELECTRIC trial office, who will receive the 
allocation information from CHaRT. The local PI will record the allocated group in a separate file and 
inform the CH staff who will deliver the allocated intervention.  
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[17b] Procedure for unblinding if needed  
We do not anticipate any requirement for unblinding but if required, the Trial Manager, Data 
Coordinator, Implementation Support Facilitators and Care Home Managers will have access to 
group allocations and any unblinding will be reported. 
 
Data collection and management 
[18a] Plans for assessment and collection of outcomes 
Outcomes will be measured at 6, 12 and 18 weeks post randomisation. The primary outcome is the 
volume of urine leaked in 24 hours at 6 weeks post randomisation, as measured by a 24-hour PWT40. 
PWTs at 12 and 18 weeks measure the sustainability of any effect. The test is based on the premise 
that 1g fluid weight = 1 ml urine and is thus an objective measure of urine leakage. The PWT involves 
the resident emptying their bladder, applying a clean, dry pad at an agreed set time and retaining all 
pads used between this time and 24 hours later. To maintain the moisture in the removed pads and 
prevent evaporation all collected pads will be individually sealed in a small plastic bag and then 
placed in a larger re-sealable bag, which is weighed onsite by the RRA after the 24-hour collection 
ends. The dry weight of the equivalent pads to those collected will be deducted from the total 
weight to provide the 24-hour volume of UI leaked.  Secondary outcome measures will include the 
number of pads used in 24 hours, which may be expected to reduce if TPTNS is effective in reducing 
volume of UI and will be reflected in the economic evaluation.  
 
PVRU will be measured using a non-invasive portable ultrasound bladder scanner. A pilot study 
conducted with CH residents23 suggested a potential mean decrease of 55ml in PVRU following a 
TPTNS programme compared to the sham stimulation group, it is thus worth investigating whether 
this was an artefact, or whether TPTNS impacts on urinary retention in the frail older adult 
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population. Additionally, it is important to ensure that any effect of TPTNS in reducing bladder 
leakage is not as a result of an increase in retained urine volume.  
 
The PPBC36 is a single question global patient reported outcome measure of perceived bladder 
condition with six possible responses ranging from ‘My bladder condition does not cause me any 
problems at all’ to ‘My bladder condition causes me many severe problems’. It has good construct 
validity and responsiveness to change36 and is recommended as a global outcome measure for UI37. 
It will be used at each time point with residents. However, it will also be adapted in this study for use 
by family carers (FC-PBC) and CH staff (S-PBC) to offer a perspective on how they believe the 
resident feels about their bladder condition.  
 
The MTSQ37 is a five question patient reported outcome measure of degree of difficulty on a scale of 
0 to 4 completing five tasks involved in toileting. Scores range from 0 to 20, with higher scores 
indicating more difficulty. The MTSQ is a reliable and valid interviewer administered measure of 
toileting skills in physically frail older women37. It will be completed at all time-points by the resident 
and/or staff member. 
 
Quality of life is measured using the DEMQOL and DEMQOL-Proxy38, valid and reliable measures of 
health-related quality of life in people with dementia. The DEMQOL-Proxy will be completed by a 
single identified proxy for the resident. Both measures will be completed at the primary outcome 
point (6 weeks post randomisation) and at the 18 week follow up assessment. 
Economic evaluation will be undertaken using routine data available in CHs as well as information 
from the Resource Use Questionnaire (RUQ) designed for this study (Appendix 2). [Appendix 
2_ELECTRIC Trial RUQ (.doc)]  The RUQ will be administered by the RRA who will record at baseline 
the usual continence care pathway including details on usage of pads and other equipment, 
medication which may affect continence level, and (if appropriate) number of staff required to assist 
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residents to use the toilet.  At the primary outcome point (6 weeks) and 18 week follow up time-
point, the RRA will use the RUQ, in combination with the 24-hour bladder diary to update the 
continence care pathway. If residents have required any care from health professionals external to 
the CH as a result of their UI, this is also recorded on the RUQ. Staff time required for training and 
the delivery of the intervention will be recorded by each CH, including the number of hours and the 
staff grade. 
 
Process evaluation 
The longitudinal process evaluation will be undertaken concurrently with the RCT and will primarily 
involve undertaking qualitative interviews with a range of informants (Table 2). The objectives will 
be to explore the experiences of the TPTNS intervention from the perspectives of residents, family 
carers and CH staff and to explore factors affecting intervention implementation in the CH context 
and optimisation for sustainability.  Additionally, data on stimulation time and intensity with 
individual residents will be automatically recorded by the stimulation machines, which will be 
allocated for use by a single resident only, in order to ensure accurate information on stimulation is 
collected.  This objective information will be compared with diary information completed by staff.  
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Table 2: Process evaluation data collection 
Process evaluation data collection Focus of questioning/data collection 
  
Resident (with and without capacity) and/or family 
carer interviews at 6 weeks (n= 20) 
Experiences, impact and acceptability 
Resident (with and without capacity) and/or family 
carer interviews at 12 weeks (n= <20) 
Experiences of incontinence, impact and 
acceptability of TPTNS 
CH nurses/senior carer focus group interviews at 4-6 
months (n= 20, number of participants 60-100) 
Organisation and care home provision of 
continence care and influencing factors 
CH nurses/senior carer individual interviews at 4-6 
months (n= <20) 
Organisation and care home provision of 
continence care and influencing factors 
CH managers individual telephone interviews (n= 20) Care home culture, management values, 
perceived impact of continence 
intervention at the organisational level, 
economic effects. Strategic considerations 
for implementation, rollout and 
sustainability 
Fidelity to group allocation monitoring Digital photographs of electrode position 
and stimulation diaries completed by staff 
Adherence to stimulation programme  Objective recording of stimulation time and 
average intensity and stimulation diaries 
completed by staff 
24 hour bladder diaries Patterns of voiding and toilet use 
 
 
Qualitative Data Collection 
Qualitative interviews will be undertaken by a research assistant skilled in the application of 
qualitative methods and will explore experiences of TPTNS or sham stimulation and any perceived 
impact on continence status and quality of life from the perspective of the CH residents and their 
family carers. Attention will be given to understanding the intervention acceptability in the short and 
longer term, especially in comparison to other UI management strategies they may be familiar with 
and the identification of potential adherence moderating factors for future TPTNS delivery. All 
interviews will be digitally recorded and transcribed verbatim in preparation for analysis. 
Resident and/or family carer interviews: face to face semi-structured interviews will be undertaken 
with residents and/or family carers, either as individual interviews or dyads. A total of 20 interviews 
will be carried out at 6 weeks, on completion of the intervention. A maximum of 20 further 
interviews with different residents/carers will take place at the 12-week juncture. Purposive 
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sampling of resident/carers for the qualitative interviews will be undertaken on the basis of 
maximum variability sampling42 with regard to gender, age, bladder symptoms, cognitive and 
functional status and resident or carer status. Three quarters of the interviews will involve residents 
who have received the TPTNS intervention or their families. A topic guide for the semi-structured 
approach will be developed to ensure all questions of interest are addressed. Fewer interviews will 
be conducted if data saturation is reached. 
 
CH nurses/senior carer interviews: focus group (or small group) interviews will be undertaken with 
CH nurses and senior carers involved in the direct delivery of the TPTNS/sham intervention. 
Attention will be paid to understanding the organisation of care, how management works with care 
staff, level of staff turnover in the previous six months and how continence care is organised within 
the routines of the CH. One focus group per CH or, where for staffing reasons this is not possible to 
organise, 2-3 small group interviews, will be held during the month following the intervention 
completion. This will result in the equivalent of 20 focus group interviews involving 60-100 CH staff. 
Additionally, up to 20 individual interviews will be undertaken with nurses/senior carers delivering 
the intervention, to explore and elicit views which staff may be reluctant to share in a group 
interview. 
 
CH Managers: individual telephone interviews with CH managers (n= 20) will be completed at the 
end of each CH’s involvement with the study (6 months following site inception). The focus of these 
interviews will be to explore the CH culture and management values, perceived effects of the 
continence intervention at the organisational level, including any impact on culture and quality of 
care and any economic effects. Strategic considerations for implementation rollout and 
sustainability in the event that TPTNS is found to be effective will be identified and explored in 
depth. 
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[18b] Plans to promote participant retention and complete follow-up 
The CH resident population is relatively stable, with changes being largely the result of individual 
illness or death, therefore discontinuation or change of status is anticipated rather than loss to 
follow up. The collection of outcomes will be undertaken by a single RRA in each CH, who will be well 
known to the CH staff and it is anticipated this design will support good retention and follow up 
rates. 
 
[19] Data management 
Both paper based and electronic data entry will be used.  Data will be collected locally by the RRA 
and entered onto the database for screening and randomisation purposes.  Paper based Case Report 
Form (CRF) data will be delivered securely to the Trial Office for data entry.  
 
[27] Confidentiality 
All collected information will be kept strictly confidential and will be stored in accordance with the 
UK Data Protection Act 201843 and retained in accordance with the latest Directive on Good Clinical 
Practice (GCP) and local policy.  Data collected during the course of the research will be kept strictly 
confidential and only accessed by members of the trial team (or individuals from the Sponsor 
organisation or CH sites where relevant to the trial).  Participants will be allocated an individual trial 
identification number.  Participant’s details will be stored on a secure database under the guidelines 
of the 2018 General Data Protection Regulation (EU) 2016/67944.  The CHaRT senior IT manager (in 
collaboration with the CI) will manage access rights to the data set.  It is anticipated that anonymised 
trial data may be shared with other researchers to enable international prospective meta-analyses.   
 
[33] Plans for collection, laboratory evaluation and storage of biological specimens for 
genetic or molecular analysis in this trial/future use 
Not applicable, there are no biological specimens. 
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[20] Access to data 
Data may be available for collaborators on request to the CI. 
 
Analysis  
[20a] Statistical methods for primary and secondary outcomes 
All analyses will be undertaken according to a previously agreed statistical analysis plan (SAP) which 
will be agreed with the Trial Steering Group (TSC), including the independent statistician, before the 
database is locked and any data analysis commences. 
 
Main effectiveness analysis:  
All baseline characteristics, follow-up measurements and safety data will be described using the 
appropriate descriptive summary measures: mean and SD for continuous and count outcomes or 
medians and inter-quartile range if required for skewed data, numbers and percentages for 
dichotomous or categorical outcomes.  The primary outcome, measured at 6 weeks post 
randomisation, will be analysed using linear multivariable regression correcting for baseline 24- 
hours PWT, the stratification design variables and other prognostic variables; all models will include 
a random effect for CH. The statistical analysis of the primary outcome will be by intention-to-treat 
(ITT); the effects of compliance with treatment will be explored using causal models to examine if 
the allocation to treatment impacts on participant adherence and fidelity fitting of the electrodes.  
Secondary outcomes will be analysed using a similar strategy employing generalised linear models 
suitable for the outcome.  All treatment effects will be derived from these models and presented 
with 95% confidence intervals.  All analyses will be performed and reported in accordance with the 
CONSORT statement and the ICH E9 ‘Statistical Principles in Clinical Trials’45.  The main analysis will 
be performed at the end of the trial when the 18 week follow up has been completed.  
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Qualitative Research Analysis 
For the three sets of qualitative interview data separate Framework analyses will be undertaken 
with the support of QSR NVivo (version 10) data management and analysis software. This method 
permits identification and cross-classification of variables directly from digital transcriptions. The 
analytic process will consist of identifying key concepts and themes and mapping their range and 
diversity, followed by a process of interpretation where patterns of association will be investigated 
and possible reasons for these explored. In achieving this all transcripts will be summarised, charted 
and coded for recurrent themes. Specific analytic intentions are associated with each of the three 
interview data sets: 
 
Residents/family carer interviews: the framework will be developed to explore the elements of 
perceived impact and acceptability of TPTNS as a therapeutic intervention, by residents and family 
carers, in both the short-term and for the longer-term. 
 
CH staff: the focus group and individual interview framework will highlight the experience of CH staff 
in developing their new skills set and the facilitators and challenges they experience implementing 
them into routine practice. The elements of the COM-B model which formed the theoretical 
underpinning of the staff interview schedule will be key concepts in this framework. 
 
CH managers: the focus of the framework for analysing the CH managers’ interviews will be the 
cultural, economic, strategic and quality impacts associated with participating in the trial and 
implications for implementation and sustainability at the organisational level.   
 
The coherence, transparency and validity of the interpretations from these three different 
framework analyses will be assessed through regular iterative discussion between the Research 
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Assistant with qualitative research experience and the study team members with qualitative 
expertise. 
 
[21b] Interim analyses 
An independent Data Monitoring and Ethics Committee (DMEC) will review confidential interim 
analyses of accumulating data at its discretion but, at least annually.  There are no formal stopping 
rules. 
 
[20b] Methods for additional analyses (e.g. subgroup analyses) 
 
Planned subgroup analyses: 
Subgroup analyses will be carried out accordingly by: 
• gender 
• UI severity 
• dependency in toilet use 
• cognitive status  
• falls status 
 
The threshold for statistical significance for the subgroup analyses will be 0.01, reflecting the 
number of subgroup comparisons being made.  Heterogeneity of treatment effects amongst 
subgroups will be tested for using the appropriate subgroup by treatment group interactions.  
 
Process evaluation data analysis 
Process evaluation data analysis will address adherence to the stimulation programme by group, at 
6-weeks post-randomisation, the end of the stimulation programme. Characteristics of residents, 
and the stimulation programme received will be described using appropriate summary measures 
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and the proportion who received the therapeutic minimum (> 8 stimulation sessions) and the full 12 
session programme presented. Overall fidelity to the allocated group will also be assessed and 
presented to illuminate resident elements of the outcome analysis including: total stimulation time, 
mean intensity of stimulation and accuracy of electrode position. Stimulation diaries will be analysed 
to inform understanding of when, how and who delivers the electrical stimulation in practice.  
 
Economic evaluation 
The economic evaluation will compare the costs and outcomes of TPTNS compared with usual 
continence care pathways and present these in a cost consequence analysis. Unit costs will be 
attached to the individual resources identified in the RUQ (Appendix 2) [Appendix 2_ELECTRIC Trial 
RUQ (.doc)] using standard sources (including NHS Reference Costs, Unit Costs of Health and Social 
Care and British National Formulary37,46-47).  Staff training time will be costed using the appropriate 
pay scales for each site. The costs of the trainer and the materials (TPTNS machines, handbook and 
training DVD) will be based on the market rates for these items.  Data on costs will not be combined 
directly with the primary study outcome as it is likely that this will not provide a representative 
reflection of the impact of the TPTNS intervention in this older group of CH residents. Relevant 
outcomes, including the trial primary and secondary outcomes, along with important issues from the 
process evaluation will be presented alongside the costs in a cost consequence analysis.  Here the 
costs will be presented alongside the effects, both quantitative and qualitative, in a disaggregated 
format to allow flexibility in presenting what costs/effects are relevant to different stakeholders. 
 
[20c] Methods in analysis to handle protocol non-adherence and any statistical methods to 
handle missing data  
Analysis will be by intention-to-treat. It is not currently planned to impute missing values, but 
multiple imputation or other strategies within sensitivity analysis may be considered (section 20a).  
These will be pre-specified in the SAP. 
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[31c] Plans to give access to the full protocol, participant level-data and statistical code 
The full current protocol (version 2.0) is provided as an appendix to this document. Anyone 
interested in other data or documentation should contact the corresponding author. 
 
Oversight and monitoring 
[5d] Composition of the coordinating centre and trial steering committee 
The Trial Office will be based in the School of Health & Life Sciences, Glasgow Caledonian University, 
providing day to day support for the trial.  The local PI and RRA in each site will be responsible for all 
aspects of local organisation including identifying potential recruits and taking consent.  The trial will 
be supervised by the Project Management Group (PMG), which will meet every three months. The 
PMG will comprise grant holders and representatives from the Trial Office and CHaRT.  A Trial 
Steering Committee (TSC), with six independent members, will meet four times over the course of 
the trial to oversee conduct and progress.  The Stakeholder and Public Involvement Group (SPIG) will 
meet 6-9 monthly to advise on trial processes and acceptability, and also to support interpretation 
and dissemination of findings.   
 
[21a] Composition of the data monitoring committee, its role and reporting structure 
A DMEC will oversee the safety of subjects in the trial. The Committee will meet regularly to monitor 
the trial data and make recommendations as to any required modifications to the protocol or the 
termination of all or part of the trial.   
 
[22] Adverse event reporting and harms 
In this trial, all Adverse Events (AEs) or Serious Adverse Events (SAEs) occurring during an electrical 
stimulation (treatment/sham) session, or while equipment is attached to the resident’s leg, or during 
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data collection periods will be recorded. Given the previous established safety profile of TPTNS, SAEs 
are not anticipated. In this trial the following related minor AEs are potentially expected: 
• Transient skin redness at electrodes sites 
• Minor itch at electrode sites 
All AEs and SAEs will be assessed for expectedness, serious-ness, severity, and causality and will be 
reported to the DMEC and relevant regulatory bodies as required. 
 
[23] Frequency and plans for auditing trial conduct 
Three monthly PMG meetings facilitate review of trial conduct.  The TSC and DMEC will also meet to 
review conduct throughout the trial period (4 times and 3 times respectively). 
 
[25] Plans for communicating important protocol amendments to relevant parties (e.g. trial 
participants, ethical committees) 
The Investigators will conduct the trial in compliance with the protocol given favourable opinion by 
the Research Ethics Committee(s) (RECs).  Any amendment to the trial will be approved by the 
Sponsor and funder before application to the RECs, unless in the case of immediate safety measures 
when the Sponsor will be notified as soon as possible.  Any deviations from the Protocol will be fully 
documented using a breach report form.  The CHs will be notified of any protocol amendments and 
a copy of the revised protocol will be sent to the PI to add to the Investigator Site File. 
 
[31a] Dissemination plans 
The authors plan to publish the findings in a range of practice focused journals and publications and 
make use of social media to enable rapid dissemination of not only the research results but also 
information on training and how to implement TPTNS into practice, if the results indicate it is 
effective.  Short, plain English summaries will be prepared to disseminate the findings to user groups 
and members of the public through websites, newsletters and social media. 
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Discussion 
UI is highly prevalent in residential and nursing CHs and has a profound impact on dignity and quality 
of life2.  Currently CHs use a containment approach to managing UI, predominantly using absorbent 
pads8.  These are not only uncomfortable and undignified for the individual but are costly to the CH 
and health service providers.  Anti-cholinergic drugs can also be used to treat UI but may have 
significant adverse effects in older adults and can adversely interact with drugs used to treat 
dementia21. 
 
TPTNS is a non-invasive intervention that has demonstrated effectiveness at reducing UI in adults23.  
However, there is a lack of evidence-based research into the safety, acceptability and effectiveness 
of its use in frail older adults.  The ELECTRIC Trial will test the feasibility and effectiveness of CH staff 
delivering TPTNS to adults in CHs. Economic evaluation will assess the costs of providing a 
programme of TPTNS and the process evaluation will provide valuable information on the 
experiences of TPTNS from the point of view of CH residents, family members, CH staff and 
managers. 
 
Should TPTNS be shown to be an effective and acceptable treatment for UI in older adults in CHs, it 
will provide a safe, low-cost and dignified alternative to the current standard approach of 
containment and medication. 
 
Trial status 
The ELECTRIC trial is currently recruiting in 5 UK Care Homes and has completed recruitment in 38 
homes.  The first patient was randomised in February 2018, with current recruitment at 371 
participants. Recruitment is due to be completed at the end of July 2019 and follow-up will be 
completed by the end of December 2019.  The TSC and DMEC have convened three times. For 
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updates see Clinical-Trials.gov and the ELECTRIC trial website48. The current version of the trial 
protocol (version 2.0) is provided in Appendix 2. [ Appendix 2_ELECTRIC Trial RUQ (.doc)] 
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